Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.

Vocka M, Zimovjanova M, Bielcikova Z, Tesarova P, Petruzelka L, Mateju M, Krizova L, Kotlas J, Soukupova J, Janatova M, Zemankova P, Kleiblova P, Novotny J, Konopasek B, Chodacka M, Brychta M, Sochor M, Smejkalova-Musilova D, Cmejlova V, Kozevnikovova R, Miskarova L, Argalacsova S, Stolarova L, Lhotova K, Borecka M, Kleibl Z.

Cancers (Basel). 2019 May 28;11(6). pii: E738. doi: 10.3390/cancers11060738.

2.

Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report.

Stanek L, Springer D, Konopasek B, Vocka M, Tesarova P, Syrucek M, Petruzelka L, Vicha A, Musil Z.

Oncol Lett. 2017 Dec;14(6):7545-7548. doi: 10.3892/ol.2017.7167. Epub 2017 Oct 11.

3.

Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.

Tesarova P, Zima T, Kubena AA, Kalousova M.

Tumour Biol. 2017 Jul;39(7):1010428317702902. doi: 10.1177/1010428317702902.

PMID:
28695773
4.

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.

Skerenova M, Mikulova V, Capoun O, Zima T, Tesarova P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Sep;161(3):272-280. doi: 10.5507/bp.2017.022. Epub 2017 May 16.

5.

Specific Aspects of Breast Cancer Therapy of Elderly Women.

Tesarova P.

Biomed Res Int. 2016;2016:1381695. Epub 2016 Oct 11. Review.

6.

Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study.

Samal F, Stanek L, Filip M, Haninec P, Vícha A, Musil Z, Tesarova P, Petruzelka L, Springer D, Kralickova M, Kohoutova M, Zima T.

Mol Clin Oncol. 2016 Jul;5(1):161-164. Epub 2016 May 10.

7.

Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients.

Hensler M, Vančurová I, Becht E, Palata O, Strnad P, Tesařová P, Čabiňaková M, Švec D, Kubista M, Bartůňková J, Špíšek R, Sojka L.

Oncoimmunology. 2015 Dec 10;5(4):e1102827. eCollection 2016 Apr.

8.

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets.

Tesarova P, Kalousova M, Zima T, Tesar V.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):1-10. doi: 10.5507/bp.2016.003. Epub 2016 Feb 3. Review.

9.

Does patient education work in breast cancer? Final results from the global CARIATIDE study.

Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P, Barni S, Deschamp V.

Future Oncol. 2015;11(2):205-17. doi: 10.2217/fon.14.179.

PMID:
25591836
10.

Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.

Rordorf T, Hassan AA, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B; Central European Cooperative Oncology Group (CECOG); Swiss Group for Clinical Cancer Research (SAKK).

Breast. 2014 Oct;23(5):511-25. doi: 10.1016/j.breast.2014.05.023. Epub 2014 Jun 27.

11.

Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.

Ušiaková Z, Mikulová V, Pintérová D, Brychta M, Valchář J, Kubecová M, Tesařová P, Bobek V, Kološtová K.

In Vivo. 2014 Jul-Aug;28(4):605-14.

PMID:
24982230
12.

The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.

Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P, Barni S, Deschamp V.

Breast. 2014 Aug;23(4):393-9. doi: 10.1016/j.breast.2014.02.009. Epub 2014 Mar 24.

13.

Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.

Mikulová V, Cabiňaková M, Janatková I, Mestek O, Zima T, Tesařová P.

Scand J Clin Lab Invest. 2014 Mar;74(2):132-42. doi: 10.3109/00365513.2013.864784. Epub 2013 Dec 19.

PMID:
24350991
14.

Breast cancer in the elderly-Should it be treated differently?

Tesarova P.

Rep Pract Oncol Radiother. 2012 Jul 15;18(1):26-33. doi: 10.1016/j.rpor.2012.05.005. Review.

15.

Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.

Germanová A, Germanová A, Tesarová P, Jáchymová M, Zvára K, Zima T, Kalousová M.

Cancer Invest. 2009 Jul;27(6):655-60. doi: 10.1080/07357900802350822.

PMID:
19452310
16.

Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer.

Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L, Zima T.

Cancer Invest. 2007 Dec;25(8):720-5.

PMID:
18058469

Supplemental Content

Loading ...
Support Center